USPTO serial 79413864
MEDINCELL.
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 16, 2026
- Examiner
- KELLY, JOHN M
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with MEDINCELL.?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jonathan M. Gelchinsky
Jonathan M. Gelchinsky Pierce Atwood LLP254 Commercial StreetPortland, ME 04101United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations and substances for use in contraception, for the treatment of schizophrenia, bipolar disorder, bipolar depression, and major depressive disorders, and for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; veterinary preparations and substances for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, diseases and disorders, and for the treatment of substance abuse related diseases and disorders; pharmaceutical compositions for use in contraception, for the treatment of schizophrenia, bipolar disorder, bipolar depression, and major depressive disorders, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, diseases and disorders, and for the treatment of substance abuse related diseases and disorders; chemical preparations for medical or pharmaceutical use for use in contraception, for the treatment of schizophrenia, bipolar disorder, bipolar depression, and major depressive disorders, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; carriers for pharmaceutical and veterinary preparations being drug delivery agents in the form of dissolvable films, and coatings for tablets that facilitate the delivery of pharmaceutical and veterinary pharmaceutical preparations for use in contraception, for the treatment of schizophrenia, bipolar disorder, bipolar depression, and major depressive disorders, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; bacteriological culture or cell culture mediums for pharmaceutical and veterinary preparations being drug delivery agents comprised of compounds for facilitating the delivery of pharmaceutical and veterinary pharmaceutical preparations for use in contraception, for the treatment of schizophrenia, bipolar disorder, bipolar depression, and major depressive disorders, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; pharmaceutical and veterinary preparations and substances for subcutaneous delivery for use in contraception, for the treatment of schizophrenia, bipolar disorder, bipolar depression, and major depressive disorders, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders | ACTIVE | — |
| 009 | Scientific apparatus and instruments, namely, tools for injecting and administering liquid formulations into testing equipment or other drug delivery devices; laboratory apparatus and instruments for extracting excipients or active pharmaceutical ingredients from in situ forming depots, not for medical purposes; apparatus and instruments for chemical analysis, namely, plates, glass slides or chips having multi-well arrays that can be used in chemical analysis; apparatus and instruments for measuring, testing and analysing chemical compositions; apparatus for analysing gases; weighing apparatus and instruments; measuring apparatus and instruments, namely, flow controllers; recorded or downloadable computer software for the quantitative long-term monitoring of the release pharmaceutical ingredients into a patient's body; computer hardware | ACTIVE | — |
| 042 | Laboratory research, testing and research laboratory analysis services in the field of drug delivery; laboratory services, namely, medical research laboratories; chemical analysis; medical, scientific and industrial research in the field of long-acting injectable compositions and providing information relating thereto; pharmaceutical drug development services; pharmaceutical research and development services; rental of laboratory apparatus and instruments; design and development of laboratory and diagnostic apparatus; development and testing of algorithms and software; consultancy in the field of pharmaceutical research and development; services for assessing the efficiency of pharmaceuticals; providing medical and scientific research information in the field of pharmaceuticals, chemical analysis and clinical trials; providing scientific research information; scientific research in the fields of medicine, pharmacology and veterinary medicine | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by MedinCell S.A.
- Other trademarks owned by MedinCell S.A.
- Other trademarks owned by MedinCell S.A.
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 042
- Similar marks named MEDINCELL.
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 16, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jun 18, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jun 16, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jun 16, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 1, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| May 31, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Apr 28, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 28, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 23, 2026 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Apr 22, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 8, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Apr 8, 2026 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Mar 28, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 27, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 27, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 27, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 15, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Oct 29, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 29, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 2, 2025 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Oct 2, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 2, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 2, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Oct 2, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Sep 11, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 10, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 6, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 5, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 5, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 2, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |